- IPO date: November 8, 2021
- Denomination: MaaT Pharma
- ISIN code/ticker: FR0012634822 / MAAT
- ICB classification: 20103010 – Biotechnology
- Listing market: Euronext Paris regulated market
- Eligible for the PEA and PEA-PME schemes and for the 150-0 B ter scheme of the CGI
- Analysts covering the share:
- Gilbert Dupont Groupe Société Générale : Pierre-Alexandre Desir & Guillaume Cuvillier
- KBC Securities: Thomas Vranken & Jacob Mekhael
- Kempen: Suzanne van Voorthuizen & Luísa Morgado
- Kepler Cheuvreux: Christophe Dombu
- Portzamparc Groupe BNP Paribas: Mohamed Kaabouni
- Stifel: Clémence Thiers & Eric Le Berrigaud
Enhancing Survival Through Innovative Immune Modulation
We have a strong oncology pipeline with multiple near-term value inflection milestones.
Replay of Webinar on Phase 3 Results in aGvHD
Stock information
Events & Presentations
Upcoming
March 17-19 • BIO-Europe Spring
March 18-19 • Microbiome Times Forum
2025
February 2025 – Corporate Presentation
ARES Phase 3 Results Company Call Presentation
Past
2024
- December 17th, 2024- KOL discussion on unmet needs in acute Graft-versus-Host Disease and the latest data on MaaT013 from the Early Access Program presented at ASH 2024.
- November, 21st 2024 – SFGM-TC Annual Congress – Pooled fecal allogenic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease: results from the EAP in Europe – by Florent Malard, MD, PhD – Professor of Hematology at Sorbonne University, INSERM and Saint-Antoine Hospital in Paris, France
- October, 25th 2024 – SEHH Congress – Allogeneic fecal microbiotherapy as a treatment for refractory Graft-versus-Hostacute gastrointestinal disease: results of the EAP in Europe – by Dr. Jaime Sanz Caballer – Hematologist and coordinator of the Bone Marrow Transplant Unit, University Hospital La Fe in Valencia, Spain
- April, 17th 2024 – EBMT Annual Congress – Presentation of Early Access Program in 140 patients with acute GvHD treated with MaaT013 by Florent Malard, MD, PhD – Professor of Hematology at Sorbonne University, INSERM and Saint-Antoine Hospital in Paris, France
2023
- December 18th, 2023- KOL discussion on data presented at ASH 2023 Annual Meeting
2022
- 2022 – Operation Note
2021
2021 – Financial Annual Report – Only in French
Provisional financial calendar*
2025*
- March 26 or 27, 2025: Publication Annual Results
- May 13, 2025: Publication of revenues & cash for T1 2025
- TBD: Annual General Meeting
- September 17 or 18, 2025: Publication of S1 results
- November 4, 2025: Publication of revenues & cash for T3 2025
*Indicative calendar could be subject to change.
Regulated Informations
Our latest report
_
Our past reports
2024
- 2024- Half-Year Financial Report (French-only)
- 2023 Universal Registration Document (French-only)
2023
- 2023 Half-Year Financial Report (French Only)
- 2022 Universal Registration Document (French Only)
2022
- 2022 – Half Year Financial Report(French Only)
- 2022 – Universal Registration Document (French Only)
- May 31, 2022 – Information on the compensation of corporate officers
- February 09, 2022 – Number of shares and voting rights (French Only)
- January 26, 2022 – Number of voting rights
- January 03, 2022 – Number of shares and voting rights (French Only)
Shareholder Meetings
Our latest meeting
_
Our past meetings
2024 - Annual Combined General Meeting - Documents
Preparatory Documents
- Convening notice (French Only)
- Convening Notice_corrective BALO (French Only)
- Convening Notice (English Only)
- MaaT Pharma – Text of resolutions OAEGM 2024 EN
- MaaT Pharma – Request for additional document
- MaaT Pharma – ENG Convening Notice May 28 2024_published
- Meeting Notice AGM 2024
- Notice of meeting BALO announcement – initial (French Only)
- Report of the Board of Directors to GM2024
- Use of delegation (French Only)
- Voting Rights published on May 6, 2024
2023 - Annual Combined General Meeting - Documents
Preparatory documents
- Notice of meeting BALO announcement (French Only)
- Convening Notice AGM
- Information on the total number of voting rights and shares comprising the share capital on May 12, 2023
- AGM voting form (French Only)
- Request for additional documents and information
- Report of the Board of Directors to GM2023
- Text of resolutions OAEGM 2023 EN
- MaaT Pharma AGM_Renewals of terms of office BoD members
- Appointment Proposal for an Independent Director: Karim Dabbagh, PhD
- Appointment Proposal for an Independent Director: Nadia Kamal
- Statutory Auditors report – AGM 190623 – Compensations (French Only)
- Statutory Auditors report – AGM 190623 – Financial results (French Only)
- Statutory Auditors’ special report – AGM 190623 – regulated agreements (French Only)
2022 - Annual Combined General Meeting documents
- Minutes of the annual combined general meeting (French Only)
- Result of the votes on the resolutions of the annual combined general meeting (French Only)
- Meeting Notice
- Board report EGM
- AGM Convening notice 2022
- Request for additional document
- AGM – Special report Free shares
- Special report on Stock Options
- Text of resolutions AGM
- List of Directors and CEO
- April 25, 2022 – Number of voting rights
- Notice of meeting BALO announcement (French Only)
- AGM voting form
Statutory Auditors Reports – (Documents in French Only)
2022 - Combined General Meeting - (ordinary & extraordinary)
- Minutes of the combined general meeting (ordinary and extraordinary) (French Only)
- Result of the vote on the resolutions of the combined general meeting (ordinary and extraordinary) (French Only)
- Convening notice 2022
- General Meeting voting form
- Report of the board – Combined general meeting
- Auditors’ reports on the share capital decrease (French Only)
- List of directors and CEO
- Ordinary and extraordinary Shareholders’ General Meeting – Press Release
- Notice of meeting to the ordinary and extraordinary General Meeting (French Only)
MaaT Pharma CSR Policy
“Patients are our priority. MaaT Pharma aims to become the source of Microbiome excellence providing patients with safe and innovative medicines. The Company develops products from sustainable biological matters, driving optimal impact of Microbiome.
We are committed to our patients and to the protection of human health by respecting environmental protection, respecting our employees, and ensuring good governance practices. Our way of working every day is driven by the 4 guidelines below :
– Innovate and raise awareness to deliver better care,
– Contribute to employees-growth within a people-oriented ecosystem,
– Place ethics and transparency at the core of the Company’s strategy,
– Control and measure our impact on the environment.
We, MaaTiens, are committed to this approach.”
Hervé Affagard, CEO of MaaT Pharma
2023
- June 2023 – CSR Report 2022 (French Only)
Corporate profile
We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Investor contact
Guilhaume Debroas, PhD.
Head of Investor Relations
Email: invest@maat-pharma.com
Phone: +33 (0) 6 16 48 92 50
MaaT Pharma
70 avenue Tony Garnier
69007 Lyon
